转移性胰腺癌短期与长期生存者的患者及疾病特征比较
该回顾性全国研究纳入2015-2022年荷兰癌症登记中接受姑息系统治疗的同步转移性胰腺腺癌患者2862例,比较短生存者(<90天)与长生存者(>365天)的治疗前特征,发现长生存者体力状态更好、心血管合并症更少、肿瘤更小、CA19-9更低且白蛋白和LDH更常正常,多因素分析提示年龄、体力状态、心血管病、低白蛋白血症、LDH和胆红素升高为不良预后因素。
要点
- 长生存者更多接受FOLFIRINOX方案(82% vs 61%)。
- 仅肺转移在长生存者中更常见,多部位转移在短生存者中占主导。
- 糖尿病、较低CA19-9和仅肺转移与更长生存相关。
核心结论
- 患者和肿瘤特异性特征强烈影响接受系统治疗的转移性胰腺癌患者生存,可支持诊断时更详细的风险分层以优化治疗选择。
研究设计与样本
- 回顾性全国研究纳入2015-2022年荷兰癌症登记中诊断同步转移性胰腺腺癌并接受姑息系统治疗的患者2862例。
主要发现
- 2862例患者中18%为长生存者(>365天),30%为短生存者(<90天)。
- 长生存者治疗前体力状态更好、心血管合并症更少、肿瘤更小、CA19-9更低,白蛋白和LDH正常者更多。
- 仅肺转移在长生存者中更常见,多部位转移在短生存者中占主导。
- 长生存者更多接受FOLFIRINOX(82% vs 61%)。
- 多因素分析显示年龄较大、体力状态差、心血管病、低白蛋白血症、LDH和胆红素升高为不良预后因素,糖尿病、较低CA19-9和仅肺转移与更长生存相关。
临床怎么用
- 诊断时可依据年龄、体力状态、心血管合并症、白蛋白、LDH、胆红素、CA19-9及转移部位进行风险分层。
- 风险分层有助于优化治疗选择,避免过度治疗和治疗不足,使照护与患者期望和价值观一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The study aims to identify prognostic pre-treatment characteristics in patients with metastatic pancreatic adenocarcinoma (mPAC) initiating systemic therapy stratified for short- and long-term survival, to support personalised treatment and improve palliative care outcomes. METHODS: This retrospective nationwide study included patients diagnosed with synchronous mPAC and registered in the Netherlands Cancer Registry, 2015-2022, who received palliative systemic therapy. Patient, tumour and treatment characteristics were compared between short-term survivors (STS) (survival <90 days since diagnosis) and long-term survivors (LTS) (survival >365 days since diagnosis). A multivariate analysis was conducted to assess the independent prognostic value of various characteristics on short- and long-term survival outcomes. RESULTS: Among 2862 patients with mPAC, 18 % were LTS and 30 % STS. LTS showed better pre-treatment performance status, fewer cardiovascular comorbidities, smaller tumours, lower CA19-9 levels, and more frequently normal albumin and LDH levels. Lung-only metastases occurred more frequently in LTS, while multiple sites predominated in STS. LTS were more often treated with FOLFIRINOX (82 % vs. 61 %). Multivariable analysis showed that older age, poor performance, cardiovascular disease, hypalbuminaemia, elevated LDH and bilirubin levels were prognostic factors indicating worse survival, while diabetes, lower CA19-9 levels, and lung-only metastases favoured longer survival. CONCLUSION: Patient- and tumour-specific characteristics strongly influence survival in mPAC patients receiving systemic therapy. These findings can support a more detailed risk stratification at diagnosis to optimise treatment selection, avoid both over- and undertreatment, and align care with individual patient expectations and values for more personalised treatment strategies.
引用
- Graus MUJE, van Diepen AE, Broekman T, et al. Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Eur J Cancer. 2026. PMID: 41633315. doi:10.1016/j.ejca.2026.116263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。